Retrophin, Inc. (NASDAQ:RTRX) Ratings Summary on Jan 9, 2019

Retrophin, Inc. (NASDAQ:RTRX) Corporate Logo
Big Money Sentiment decreased to 1.08 in Q3 2018. It has change of 0.24, from 2018Q2’s 1.32. The ratio is negative due to Retrophin, Inc. positioning: 16 sold and 34 reduced. 22 funds bought holdings and 32 increased holdings. Investors holded 40.01 million in 2018Q2 but now own 41.12 million shares or 2.80% more.
Citigroup Incorporated reported 24,757 shs stake. Panagora Asset Mgmt has invested 0.01% in Retrophin, Inc. (NASDAQ:RTRX). Blair William And Il holds 0% or 8,000 shs. Sei Invs Company invested in 617 shs. Tudor Et Al reported 46,538 shs. 40,700 are held by State Of Wisconsin Inv Board. Connor Clark Lunn Investment Management Limited holds 13,150 shs. Wellington Mngmt Gp Limited Liability Partnership holds 0% or 33,902 shs. New York State Common Retirement Fund invested in 44,500 shs. Perceptive Advsr Limited Liability Corp has 3.21 million shs for 1.62% of their capital. National Bank Of New York Mellon Corporation has 358,737 shs for 0% of their capital. Ubs Asset Management Americas reported 0% in Retrophin, Inc. (NASDAQ:RTRX). 63,700 were reported by Swiss Savings Bank. Savings Bank Of America Corp De has invested 0% of its capital in Retrophin, Inc. (NASDAQ:RTRX). Royal Bancorporation Of Canada has invested 0% in Retrophin, Inc. (NASDAQ:RTRX).

Retrophin, Inc. had 10 insider sales and 0 insider buys since August 31, 2018. This’s net activity of $1.99 million. $120,146 worth of Retrophin, Inc. (NASDAQ:RTRX) shs were sold by REED ELIZABETH E. $240 worth of Retrophin, Inc. (NASDAQ:RTRX) was sold by ASELAGE STEVE. 11,125 Retrophin, Inc. (NASDAQ:RTRX) shs with value of $248,333 were sold by McFarlane Neil F.. Another trade for 5,000 shs valued at $120,130 was made by ROTE WILLIAM E. on Wednesday, November 14.

Retrophin, Inc. (NASDAQ:RTRX) Ratings Coverage

A total of 3 analysts rate Retrophin (NASDAQ:RTRX) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:RTRX) has 3 ratings reports on Jan 9, 2019 according to StockzIntelligence. Listed here are Retrophin, Inc. (NASDAQ:RTRX) PTs and latest ratings.

19/11/2018 Broker: Nomura Rating: Buy New Target: $57 Initiates Coverage On
30/10/2018 Broker: Jefferies Rating: Buy New Target: $44 Initiates Coverage On
17/08/2018 Broker: Canaccord Genuity Rating: Buy New Target: $36 Initiates Coverage On

RTRX touched $23.23 during the last trading session after $0.48 change.Retrophin, Inc. has volume of 102,960 shares. Since January 9, 2018 RTRX has risen 11.46% and is uptrending. The stock outperformed the S&P 500 by 11.46%.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.The firm is worth $958.18 million. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.Last it reported negative earnings. The companyÂ’s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

For more Retrophin, Inc. (NASDAQ:RTRX) news released recently go to:,,, or The titles are as follows: “Retrophin, Inc. (RTRX) CEO Steve Aselage on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” released on November 01, 2018, “15 years in prison for Shkreli? – Seeking Alpha” on March 07, 2018, “Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis – GlobeNewswire” with a publish date: October 26, 2018, “Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy – Nasdaq” and the last “Retrophin (RTRX) Complete Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN –” with publication date: December 20, 2018.

Retrophin, Inc. (NASDAQ:RTRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.